The FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with ...

The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

LEQVIO marks a significant advancement in hypercholesterolemia management, particularly for patients not achieving target LDL-C levels despite maximally tolerated statin therapy. As the first FDA ...

For Leqvio’s launch, Novartis is taking a population health-based approach at 200 large U.S. healthcare systems in an effort to identify eligible patients. Among them, at least 50 systems have ...

LEQVIO works with the liver's natural processes and can help lower LDL-C by 50%. It is not known if LEQVIO can decrease problems related to high levels of bad cholesterol, such as heart attacks or ...

Novartis AG NVS 0.90% bet big on its new cholesterol-busting drug. To overcome the tricky market for new heart medicines, it is pursuing an unconventional strategy that turns the traditional drug ...